The pharmacogenetics of aripiprazole-induced hyperprolactinemia: what do we know?

Pharmacogenomics. 2020 Jun;21(9):571-574. doi: 10.2217/pgs-2020-0024. Epub 2020 May 13.

Authors

Dora Koller¹, Francisco Abad-Santos^{1

2}

Affiliations

¹ Clinical Pharmacology Department, Hospital Universitario de La Princesa, Instituto Teófilo Hernando, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.
² UICEC Hospital Universitario de La Princesa, Platform SCReN (Spanish Clinical Research Network), Instituto de Investigación Sanitaria La Princesa (IP), Madrid, 28006, Spain.

PMID: 32397867
DOI: 10.2217/pgs-2020-0024

No abstract available

Keywords: antipsychotics; aripiprazole; pharmacogenetics; prolactin.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Antipsychotic Agents / adverse effects*
Antipsychotic Agents / metabolism
Aripiprazole / adverse effects*
Aripiprazole / metabolism
Humans
Hyperprolactinemia / chemically induced*
Hyperprolactinemia / genetics
Hyperprolactinemia / metabolism
Pharmacogenetics / methods*
Pharmacogenetics / trends
Receptors, Dopamine / genetics
Receptors, Dopamine / metabolism
Receptors, Serotonin / genetics
Receptors, Serotonin / metabolism

Substances

Antipsychotic Agents
Receptors, Dopamine
Receptors, Serotonin
Aripiprazole